Figure S3 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

Key Points

• Combination treatment improves effectiveness against MTAP-deleted KRAS-mutant pancreatic cancer, showing potential for clinical application.
• In vitro analysis demonstrates that using PRMT5 inhibitors with KRAS inhibitors provides a synergistic effect, highlighting their therapeutic potential.
• This approach employs targeted therapies to address specific mutations in pancreatic cancer, which could enhance treatment options for affected patients.
• The findings suggest a shift towards personalized medicine in pancreatic cancer treatment strategies, focusing on genetic profiling.

Abstract